New Surveys Reveal Striking Differences Between Public Perceptions and Private Realities of People With Fibromyalgia
ROCKLIN, Calif., March 21, 2012 /PRNewswire/ -- In a unique approach that compares the attitudes of people living with fibromyalgia with those of the general public, the American Chronic Pain Association (ACPA) in partnership with Forest Laboratories Inc.

Commercializing Pancreatic Cancer Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others
NEW YORK, March 15, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Commercializing Pancreatic Cancer Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others This report will excel your competitive awareness and decrease your decision making time in managing pancreatic cancer drug development.

Leading Anti-Cancer Drugs and Associated Market 2012-2022
NEW YORK, April 2, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Leading Anti-Cancer Drugs and Associated Market 2012-2022 Report Details Cancer treatments - discover which products have greatest potential  Where are cancer-treating drugs heading? Visiongain's report shows you potential revenues to 2022, with data, forecasts and discussions. This study investigates leading drugs to treat human cancers.

Diabetes Therapeutics Market to 2017 - Better Glycemic Control and Reduced Potential Risk of Hypoglycemia to Increase the Market Share of DPP-IV Inhib
NEW YORK, March 6, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Diabetes Therapeutics Market to 2017 - Better Glycemic Control and Reduced Potential Risk of Hypoglycemia to Increase the Market Share of DPP-IV Inhibitors and GLP-1 Agonists Diabetes Therapeutics Market to 2017 - Better Glycemic Control and Reduced Potential Risk of Hypoglycemia to Increase the Market Share of DPP-IV Inhibitors an ...